共 50 条
- [41] A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic LeukemiaBLOOD, 2019, 134Jain, NitinStevenson, Kristen E.Winer, Eric S.Garcia, Jacqueline S.Stone, Richard M.Jabbour, EliasRavandi, FarhadStewart, Jeremy M.Legg, Dean R.Kantarjian, Hagop M.Neuberg, Donna S.Letai, Anthony G.Konopleva, Marina Y.DeAngelo, Daniel J.
- [42] Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD, With or Without Blinatumomab, Is Highly Effective in Patients With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First SalvageCANCER, 2018, 124 (20) : 4044 - 4055Jabbour, EliasSasaki, KojiRavandi, FarhadHuang, XuelinShort, Nicholas J.Khouri, MariaKebriaei, PartowBurger, JanKhoury, JosephJorgensen, JeffreyJain, NitinKonopleva, MarinaGarcia-Manero, GuillermoKadia, TapanCortes, JorgeJacob, JovittaMontalbano, KathrynGarris, RebeccaO'Brien, SusanKantarjian, Hagop M.
- [43] Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemiaHAEMATOLOGICA, 2024, 109 (09) : 3042 - 3047Gibson, AmberNunez, CesarRobusto, LindsayKammerer, BriannaGarcia, MiriamRoth, MichaelSheth, RachnaTewari, PritiHittle, AlineToepfer, LaurieTorres, RomeoShort, Nicholas J.Jabbour, EliasJain, NitinCuglievan, BrankoMcCall, David
- [44] Phase II Study of Pedi-Crib: Mini-Hyper-CVD with Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric Patients with B-Cell Lineage Acute Lymphocytic LeukemiaBLOOD, 2024, 144 : 14311 - 14312Mccall, DavidGibson, AmberGarcia, Miriam B.Nunez, CesarRoth, Michael E.Cuglievan, Branko
- [45] A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemiaBLOOD ADVANCES, 2024, 8 (04) : 909 - 915Short, Nicholas J.Jabbour, EliasJain, NitinSenapati, JayastuNasr, LewisHaddad, Fadi G.Li, ZhenhuaHsiao, Yu-ChihYang, Jun J.Pemmaraju, NaveenOhanian, MaroWierda, William G.Montalban-Bravo, GuillermoBorthakur, GautamHan, LinaXiao, LianchunHuang, XuelinAbramova, ReginaZhao, MinGarris, RebeccaKonopleva, MarinaRavandi, FarhadKantarjian, Hagop
- [46] Mini-hyper-CVD plus inotuzumab ozogamicin (InO), with or without blinatumomab (Blina), in older patients with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL): Updates from a phase II trialJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Nasnas, Cedric ChristopheJabbour, EliasHaddad, FadiShort, Nicholas JamesNasr, Lewis FadyMacaron, WalidZoghbi, MarianneRavandi, FarhadJain, NitinKadia, Tapan M.Daver, Naval GuastadBorthakur, GautamDinardo, Courtney DentonJacob, JovittaRoy, EdithLoiselle, ChristopherMilton, AnnaRivera, JuanGarris, RebeccaKantarjian, Hagop M.
- [47] Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic LeukemiaBLOOD, 2024, 144 : 1442 - 1443Senapati, JayastuJabbour, EliasShort, Nicholas J.Jain, NitinHaddad, Fadi G.Kadia, Tapan M.Sasaki, KojiAlvarado-Valero, YesidTakahashi, KoichiDinardo, Courtney D.Daver, NavalGarcia-Manero, GuillermoRavandi, FarhadJacob, JovittaGarris, RebeccaKantarjian, Hagop
- [48] Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemiaCANCER, 2021, 127 (12) : 2025 - 2038Jabbour, EliasSasaki, KojiShort, Nicholas J.Ravandi, FarhadHuang, XuelinKhoury, Joseph D.Kanagal-Shamanna, RashmiJorgensen, JeffreyKhouri, Issa F.Kebriaei, PartowJain, NitinAlvarado, YesidKadia, Tapan M.Paul, ShilpaGarcia-Manero, GuillermoDabaja, Bouthaina S.Burger, Jan A.DiNardo, Courtney D.Daver, Naval A.Montalban-Bravo, GuillermoYilmaz, MusaOhanian, MaroFerrajoli, AlessandraJacob, JovittaRostykus, MeaganGarris, RebeccaO'Brien, SusanKantarjian, Hagop M.
- [49] Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic LeukemiaBLOOD, 2024, 144 : 1439 - 1441Nguyen, DanielKantarjian, HagopShort, Nicholas J.Jain, NitinHaddad, Fadi G.Yilmaz, MusaFerrajoli, AlessandraKadia, Tapan M.Valero, Yesid AlvaradoMaiti, AbhishekZoghbi, MarianneSenapati, JayastuGarris, RebeccaZhao, MinKonopleva, MarinaRavandi, FarhadJabbour, Elias
- [50] Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic LeukemiaBLOOD, 2023, 142Nguyen, DanielKantarjian, Hagop M.Short, Nicholas J.Jain, NitinHaddad, Fadi G.Yilmaz, MusaFerrajoli, AlessandraKadia, Tapan M.Valero, Yesid AlvaradoMaiti, AbhishekNasnas, CedricNasr, LewisGarris, RebeccaKonopleva, Marina Y.Ravandi, FarhadJabbour, Elias